Skip to content
DataLookout
Menu

NCT06203470

Botox Versus Tacrolimus in Psoriasis Vulgaris

StatusUnknown
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Jun 2024); last known: Not Yet Recruiting
  2. Notable Primary endpoint revisedv2 Show 4 more changesShow less
    • Interventions: Botulinum Toxin-A (Drug), calcipotriol (Drug) to Botulinum Toxin-A (Drug), Tacrolimus (Drug)
    • Publications revised (17)
    • Study title revised
    • Study description shortened, about 1 word
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

To evaluate the efficacy and safety of Mesobotox for treatment of plaque psoriasis as a monotherapy versus its combination with a topical Calcineurin inhibitor 0.03% ointment and topical Calcineurin inhibitor 0.03% ointment alone.
Timeframe: 6 months

Secondary (2)

To explore the treatment effects on the histopathological features of psoriasis.
To explore the treatment effects on the immunohistochemical features of psoriasis.

Arms and interventions

Botox groupExperimental

Patients will receive a single intradermal injection of Mesobotox as a monotherapy. Botulinum toxin injection: Botox injections will be intradermal. Concentration will be 100 U to be diluted with 5-ml sterile physiological sodium chloride solution. Each patient will receive individual injections of 1 U using a grid with points set at a distance of 1 cm apart. Up to two plaques per patient will be selected, whose diameter would not exceed 5-10 cm2. Each patient will receive a single BoNT-A injection

Botox and Tacrolimus groupExperimental

Patients will receive a single intradermal injection of Mesobotox of the same dilution followed by topical application of Tacrolimus 0.03% ointment twice daily for 3 months.

Tacrolimus groupExperimental

Patients will apply Tacrolimus (0.03%) as a monotherapeutic twice daily for 3 months

Drugs: Botulinum Toxin-A, Tacrolimus